Table 1.

Baseline Characteristics

Baseline Characteristic	FAS (N = 88)	Safety (N = 127)
Male; n (%)	56 (63.6%)	84 (66.1%)
Age (yr); mean ± SD	65.63 ± 10.14	65.20 ± 9.72
Duration of PD (yr); mean ± SD	11.63 ± 5.95	10.38 ± 5.74
Duration of morning akinesia (yr); mean ± SD	4.53 ± 3.27	4.23 ± 2.71
UPDRS Motor Score (ON); mean ± SD	20.36 ± 9.71	20.05 ± 0.97
Duration of l‐dopa treatment (mo); mean ± SD	57.49 ± 85.49	52.09 ± 85.66
Daily l‐dopa dose (mg); mean ± SD	841 ± 512	965 ± 990
Use of adjunct medications; n (%)
Dopamine agonists	67 (76.1%)	83 (65.4%)
MAO‐B inhibitors	45 (51.1%)	59 (46.5%)
COMT inhibitors	42 (47.7%)	51 (40.2%)
Amantadine	22 (25.0%)	28 (22.0%)

SD, standard deviation; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale; MAO‐B, monoamine oxidase; COMT, catechol‐O‐methyl transferase.